Return to market of Tysabri would mark rare moveA promising drug for multiple sclerosis should be returned to the market despite questions about a rare brain disease, scientific advisers told the government Wednesday – even as they continued to grapple with just who should be allowed to use it.
The unanimous vote by advisers to the Food and Drug Administration came amid regulators' own concerns about the drug Tysabri, and whether there is any way to minimize risk from the apparent rare side effect.